Program
cariprazine
Also written as “Cariprazine”, “MP-214 3mg” and “MP-214 6mg”.
Its studies are mostly in Schizophrenia · Depressive Disorder, Major · Bipolar Disorder · Mania · Depression, led by 7 companies.
Drug pageCariprazine: every studyMany companies study it; this page follows only the 41 they lead. All 53 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AbbVie | 291 open or running | phase 3since Jan 27, 2010 | Nov 27, 2006 | Mar 2027phase 3 · NCT04777357 |
| Tanabe Pharmaits history only | 60 open or running | phase 3since Jun 19, 2012 | Mar 15, 2009 | none ahead |
| Gedeon Richter Plc.its history only | 21 open or running | phase 3since Jan 24, 2019 | Jun 13, 2014 | Dec 15, 2026phase 3 · NCT03817502 |
| Bostal Drug Deliveryits history only | 11 open or running | phase 3since Jul 15, 2026 | Jul 15, 2026 | Aug 2027phase 3 · NCT07722728 |
| Humanis Saglık Anonim Sirketiits history only | 10 open or running | phase 1since Jul 1, 2026 | Jul 1, 2026 | none ahead |
| Mapi Pharmaits history only | 11 open or running | phase 2since Aug 28, 2025 | Aug 28, 2025 | Dec 31, 2026phase 2 · NCT07185815 |
| Whanin Pharmaceuticalits history only | 10 open or running | phase 3since Nov 26, 2021 | Nov 26, 2021 | none ahead |
Also a collaborator on its studies: Gedeon Richter.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of AbbVie only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 13 studies since Nov 27, 2006.
- Jul 15, 2011Phase 2 study in Bipolar DisorderNCT01396447 · 584 enrolled · United States, Bulgaria, Canada and more
- Aug 4, 2011Phase 3 study in SchizophreniaNCT01412060 · 765 enrolled · United States, India, Romania and more
- Nov 8, 2011Phase 2 study in Depressive Disorder, MajorNCT01469377 · 819 enrolled · United States, Estonia, Finland and more
- Oct 25, 2012Phase 3 study in Depressive Disorder, MajorNCT01715805 · 1,022 enrolled · United States, Puerto Rico
- Apr 22, 2013Phase 3 study in Depressive Disorder, MajorNCT01838876 · 442 enrolled · United States, Puerto Rico
- Jan 28, 20162 phase 3 studies in Bipolar DisorderNCT02670551, NCT02670538
- Jun 5, 2018Phase 3 study in ManiaNCT03573297 · 901 enrolled · United States, Bulgaria, Korea, Republic of and more
- Jul 10, 2018Phase 3 study in SchizophreniaNCT03593213 · 587 enrolled · United States, Bulgaria, Korea, Republic of and more
- Nov 8, 20182 phase 3 studies in Depressive Disorder, MajorNCT03738215, NCT03739203
- Mar 19, 2020Phase 1 study in Autism Spectrum DisorderNCT04382885 · 24 enrolled · United States
- Feb 26, 2021Phase 3 study in DepressionNCT04777357 · 338 planned · United States, Puerto Rico, Russia
- Jul 7, 2021Phase 2 study in Generalized Anxiety DisorderNCT04965272 · United States
- May 6, 2022Phase 3 study in SchizophreniaNCT05368558 · 34 enrolled · Japan, Taiwan
- Jun 28, 2022Phase 3 study in Autism Spectrum DisorderNCT05439616 · 161 enrolled · United States, Puerto Rico
Ahead
- Mar 2027Primary completion: phase 3 study in DepressionNCT04777357
TargetBeta
“Dopamine D3 receptor modulator; Dopamine D2 receptor modulator”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Olanzapinerule | Eli Lilly | phase 4 | 76 |
| rotigotinerule | UCB | phase 4 | 64 |
| Pramipexolerule | Boehringer Ingelheim | phase 4 | 44 |
| ABBV-932 | AbbVie | phase 2 | 10 |
Studies
All 29 AbbVie leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT05439616Autism Spectrum Disorder · United States, Puerto Rico | 3 | Completed | Oct 4, 2024 | 161 |
| NCT05368558Schizophrenia · Japan, Taiwan | 3 | Terminated | Sep 20, 2024 | 34 |
| NCT04965272Generalized Anxiety Disorder · United States | 2 | Withdrawn | Aug 24, 2021 | 0 |
| NCT04777357Depression · United States, Puerto Rico, Russia | 3 | Recruiting | Mar 2027 | 338 |
| NCT04382885Autism Spectrum Disorder · United States | 1 | Completed | Dec 10, 2021 | 24 |
| NCT03739203Depressive Disorder, Major · United States, Canada, Czechia and more | 3 | Completed | Sep 6, 2021 | 752 |
| NCT03738215Depressive Disorder, Major · United States, Bulgaria, Estonia and more | 3 | Completed | Sep 30, 2021 | 759 |
| NCT03593213Schizophrenia · United States, Bulgaria, Korea, Republic of and more | 3 | Terminated | Feb 11, 2021 | 587 |
| NCT03573297Mania · United States, Bulgaria, Korea, Republic of and more | 3 | Completed | Sep 5, 2022 | 901 |
| NCT02670551Bipolar Disorder · United States, Bulgaria, Estonia and more | 3 | Completed | Jul 19, 2017 | 488 |
| NCT02670538Bipolar Disorder · United States, Bulgaria, Croatia and more | 3 | Completed | Jan 18, 2018 | 493 |
| NCT01838876Depressive Disorder, Major · United States, Puerto Rico | 3 | Completed | Jul 27, 2015 | 442 |
| NCT01715805Depressive Disorder, Major · United States, Puerto Rico | 3 | Completed | Jun 24, 2016 | 1,022 |
| NCT01469377Depressive Disorder, Major · United States, Estonia, Finland and more | 2 | Completed | Dec 12, 2013 | 819 |
| NCT01412060Schizophrenia · United States, India, Romania and more | 3 | Completed | Sep 3, 2014 | 765 |
| NCT01396447Bipolar Disorder · United States, Bulgaria, Canada and more | 2 | Completed | Jan 10, 2014 | 584 |
| NCT01376076Schizophrenia · United States | 1 | Completed | Feb 2012 | 129 |
| NCT01104779Schizophrenia · United States, Colombia, India and more | 3 | Completed | Dec 15, 2011 | 446 |
| NCT01104792Schizophrenia · United States, Colombia, India and more | 3 | Completed | Jan 31, 2013 | 752 |
| NCT01104766Schizophrenia · United States, Romania, Russian Federation and more | 3 | Completed | Dec 20, 2011 | 617 |
| NCT01059539Mania · United States, Hungary, Poland and more | 3 | Completed | Feb 29, 2012 | 403 |
| NCT01058668Mania · United States, Croatia, Romania and more | 3 | Completed | Dec 2011 | 497 |
| NCT01058096Bipolar Disorder · United States, India | 3 | Completed | Jul 2011 | 323 |
| NCT00854100Depressive Disorder, Major · United States | 2 | Completed | Dec 6, 2010 | 231 |
| NCT00852202Bipolar Disorder · United States | 2 | Completed | Jun 15, 2010 | 234 |
| NCT00839852Schizophrenia · United States, India, Malaysia and more | 2 | Completed | Aug 31, 2010 | 97 |
| NCT00694707Schizophrenia · United States, India, Malaysia and more | 2 | Completed | Aug 31, 2009 | 732 |
| NCT00488618Bipolar Disorder · United States | 2 | Completed | Jul 2008 | 238 |
| NCT00404573Schizophrenia · United States | 2 | Completed | Aug 2007 | 375 |
How it is read
Names in the registry
- “Cariprazine”, 25 entries
- “MP-214 3mg”, 3 entries
- “MP-214 6mg”, 3 entries
- “MP-214 9mg”, 3 entries
- “MP-214”, 2 entries
Conditions, from the studies’ own filings
- Schizophrenia, 21 studies
- Depressive Disorder, Major, 6 studies
- Bipolar Disorder, 6 studies
- Mania, 3 studies
- Depression, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.